Potentiating antitumor effects of a combination therapy with lovastatin and butyrate in the Lewis lung carcinoma model in mice

International Journal of Cancer

Volumn 97, Issue 6, 2002, Pages 746-750

  Giermasz, Adam ^a   Makowski, Marcin ^a   Kozłowska, Ewa ^b   Nowis, Dominika ^a   Maj, Małgorzata ^a   Jalili, Ahmad ^a   Feleszko, Wojciech ^a   Wójcik, Cezary ^a   Da̧rowska, Anna ^a,c   Jakóbisiak, Marek ^a   Goła̧b, Jakub ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b UNIVERSITY OF WARSAW   (Poland)

^c INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Butyrate; Cancer; Lovastatin; Synergism; Tributyrin

Indexed keywords

BUTYRIC ACID; CYCLIN D1; MEVINOLIN; PROTEIN P21; PROTEIN P53; TRIBUTYRIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG POTENTIATION; HYPERCHOLESTEROLEMIA; LEWIS CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARCINOMA, LEWIS LUNG; CELL CYCLE; CELL SURVIVAL; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; FLOW CYTOMETRY; FORMAZANS; LOVASTATIN; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; TETRAZOLIUM SALTS; TRIGLYCERIDES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0037138434     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10119     Document Type: Article

References (32)

1. Cell cycle-specific effects of lovastatin
2. Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2activity and redistribution of p21 and p27, independent of p53
3. Metastasis of B16F10 mouse melanoma inhibited by lovastatin, an inhibitor of cholesterolbiosynthesis
4. Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of themevalonate pathway of cholesterol synthesis
5. Potentiated antitumor effects of cisplatin and lovastatin against MmB 16 melanoma in mice
6. A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme
7. Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma
8. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer
9. Lovastatin and tumor necrosis factor-alpha exhibit potentiated antitumor effects against Ha-ras-transformed murine tumor via inhibition of tumor-induced angiogenesis
10. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells
11. Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice
12. Short chain fatty acids in the human colon
13. Sodium butyrate induction of milk-related antigens in human MCF-7 breast carcinoma cells
14. Butyrate-induced G1 arrest results from p21-independent disruption of retinoblastoma protein-mediated signals
15. Sodium butyrate induces G2 arrest in the human breast cancer cells MDA-MB-231 and renders them competent for DNA rereplication
16. Sodium butyrate induces apoptosis in human colonic turnout cell lines in a p53-independent pathway: Implications for the possible role of dietary fibre in the prevention of large-bowel cancer
17. Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors
18. Phase I trial of interleukin-2 and high-dose arginine butyrate in metastatic colorectal cancer
19. Butyrate inhibits seeding and growth of colorectal metastases to the liver in mice
20. Potentiation of antitumor effects of tumor necrosis factor alpha and interferon gamma by macrophage-colony-stimulating factor in a MmB16 melanoma model in mice
21. Criteria for analyzing interactions between biologically active agents
22. Synergistic anti-proliferative activity of tumor necrosis factor-alpha (TNF-α) and lovastatin
23. G-CSF prevents the suppression of bone marrow hematopoiesis induced by IL-12 and augments its antitumor activity in a melanoma model in mice
24. Antitumor activity of tributyrin in murine melanoma model
25. Ha-rasVall2 oncogene increases susceptibility of NIH/3T3 cells to lovastatin
26. Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity
27. Apoptosis induced by the histone deacetylase inhibitor sodium butyrate in human leukemic lymphoblasts
28. Lipid metabolism as a target for brain cancer therapy: Synergistic activity of lovastatin and sodium phenylacetate against human glioma cells
29. Effects of lovastatin on a human myeloma cell line: Increased sensitivity of a multidrug-resistant subline that expresses the 170 kDa P-glycoprotein
30. Modulation of P-glycoprotein phosphorylation and drug transport by sodium butyrate
31. Synergistic efficacy of 3n-butyrate and 5-fluorouracil in human colorectal cancer xenografts via modulation of DNA synthesis
32. Vincristine- and cisplatin-induced apoptosis in human retinoblastoma. Potentiation by sodium butyrate